COMMUNIQUÉS West-GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/08/2024
LEXINGTON, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with a newly [...]
Cytokinetics to Participate in September Investor Conferences
29/08/2024
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company is scheduled to participate in the following investor conferences in September: [...]
Radiance BioPharma sponsoring Investor Cruise Event 2024
29/08/2024
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Radiance Biopharma Inc., a biopharmaceutical company developing next generation Antibody Drug Conjugates and Bispecific Antibody Drug Conjugates announced that Robert K. Brooks [...]
EssilorLuxottica: successful Euro 2 billion bond issuance at 2.99%
29/08/2024
NOT TO BE RELEASED, PUBLISHED OR DISTRIBUTED DIRECTLY OR INDIRECTLY IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR [...]
EssilorLuxottica: Succès du placement d'une émission obligataire de 2 milliards d'euros à 2,99 %
29/08/2024
NE PAS DIFFUSER, PUBLIER OU DISTRIBUER, DIRECTEMENT OU INDIRECTEMENT, AUX ETATS-UNIS D’AMÉRIQUE, AU CANADA, EN AUSTRALIE, AU JAPON, EN AFRIQUE DU SUD OU DANS TOUTE AUTRE JURIDICTION DANS LAQUELLE IL SERAIT ILLÉGAL DE LE [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2024
29/08/2024
Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2024 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2024
29/08/2024
Nombre total de droits de vote et d’actions composant le capital social au 31 juillet 2024 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) [...]
RAMSAY SANTE : Provisional annual results at the end of June 2024
29/08/2024
PRESS RELEASE Paris, 29 th August 2024 Provisional annual results at the end of June 2024 As a mission-driven company, Ramsay Santé, thanks to its employees and medical community, is committed to expanding its [...]
RAMSAY SANTE : résultats annuels provisoires à fin juin 2024
29/08/2024
COMMUNIQUÉ DE PRESSE Paris, le 29 août 2024 Résultats annuels provisoires à fin juin 2024 Entreprise à mission, Ramsay Santé, grâce à ses collaborateurs et sa communauté médicale, s’engage à poursuivre et accélérer dans [...]
iTeos annonce sa participation aux prochaines journées Investisseurs
29/08/2024
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 29 août 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS) (« iTeos »), une société biopharmaceutique au stade clinique, pionnière dans la découverte et le [...]
Major shareholder announcement
29/08/2024
Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and [...]
Vericel to Present at the Morgan Stanley Global Healthcare Conference on Friday, September 6, 2024
29/08/2024
CAMBRIDGE, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President [...]
Anaptys Announces Participation in September Investor Conferences
29/08/2024
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president [...]
Biomerica Reports Fiscal 2024 Year End Results
29/08/2024
Total Revenue Increases 1% Year-Over-Year – Core Revenue Excluding COVID Tests Climbs 5%, Reflecting Stronger Growth Significant Cost Savings Plan Implemented After Year End – Expected to Deliver Expense Reductions of $ [...]
Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA® Label
29/08/2024
FDA Final Approval to Precision Dosing for GLOPERBA ® Label. We believe GLOPERBA ® is the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in [...]
Psychemedics Corporation Launches New Ketamine Hair Testing Service
29/08/2024
DALLAS, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing, is proud to announce the launch of its new ketamine hair testing solution. This innovative testing [...]
The International Myeloma Foundation (IMF) Brings Back ‘Do You #kNOwMyeloma?’ for Blood Cancer Awareness Month 2024
29/08/2024
LOS ANGELES, Aug. 29, 2024 (GLOBE NEWSWIRE) -- With Blood Cancer Awareness Month coming up this September, the International Myeloma Foundation (IMF) is reviving and amplifying its highly successful #kNOwMyeloma [...]
Inozyme Pharma to Participate at the 2024 Wells Fargo Healthcare Conference
29/08/2024
BOSTON, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect [...]
Femasys Announces CE Mark and Canadian Approval for FemVue® MINI, a Fallopian Tube Assessment Solution
29/08/2024
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and [...]

Pages